Deciphera Pharmaceuticals Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$108.8M
Doctors Paid
4,229
Transactions
31,262
2024 Total
$21.9M
Payment Breakdown by Category
Research$106.5M (98.0%)
Consulting$335,154 (0.3%)
Food & Beverage$218,847 (0.2%)
Travel$112,285 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $106.5M | 21,586 | 98.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.0M | 212 | 0.9% |
| Honoraria | $547,579 | 200 | 0.5% |
| Consulting Fee | $335,154 | 196 | 0.3% |
| Food and Beverage | $218,847 | 8,643 | 0.2% |
| Travel and Lodging | $112,285 | 399 | 0.1% |
| Education | $290.21 | 26 | 0.0% |
Payments by Type
Research
$106.5M
21,586 transactions
General
$2.2M
9,676 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES | $24.0M | 0 | 3,605 |
| INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE | $22.7M | 1 | 5,083 |
| INVICTUS A PHASE 3 INTERVENTIONAL DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY AND EFFICACY OF DCC-2618 IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS WHO HAVE RECEIVED TREATMENT WITH PRIOR ANTICANCER THERAPIES | $6.6M | 0 | 649 |
| A STUDY OF RIPRETINIB VS SUNITINIB IN PATIENTS WITH ADVANCED GIST WITH SPECIFIC KIT EXON MUTATIONS WHO WERE PREVIOUSLY TREATED WITH IMATINIB (INSIGHT) | $6.4M | 0 | 333 |
| A PHASE 1 STUDY TO EVALUATE THE PHARMACOKINETICS OF DCC-3014 IN HEALTHY ADULT PARTICIPANTS | $6.3M | 0 | 67 |
| A DRUG-DRUG INTERACTION STUDY TO EVALUATE THE EFFECT OF RIPRETINIB ON THE PHARMACOKINETICS OF A CYP2C8 PROBE SUBSTRATE IN PATIENTS WITH ADVANCED GIST | $5.8M | 0 | 219 |
| A MASTER PROTOCOL FOR THE MULTI-COHORT, PHASE 1/2 STUDY OF DCC-3116 IN COMBINATION WITH ANTICANCER THERAPIES IN PARTICIPANTS WITH ADVANCED MALIGNANCIES | $5.5M | 0 | 205 |
| A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) | $5.1M | 0 | 1,159 |
| A PHASE 1/2 STUDY OF DCC-3116 IN PATIENTS WITH MAPK PATHWAY MUTANT SOLID TUMORS | $4.0M | 0 | 831 |
| A PHASE 1B 2 STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH PACLITAXEL IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS | $3.1M | 0 | 2,045 |
| STUDY OF DCC-3014 IN PATIENTS WITH ADVANCED TUMORS AND TENOSYNOVIAL GIANT CELL TUMOR | $1.8M | 0 | 920 |
| A Phase 1/2, First in Human Study of DCC 3116 as Monotherapy and in Combination with RAS/MAPKPathway Inhibitors in Patients with Advanced or Metastatic Solid Tumors with RAS/MAPK Pathway Mutations | $1.7M | 1 | 547 |
| A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS | $1.6M | 0 | 1,478 |
| A Phase 1, Open-label, Randomized, Parallel Design Study to Evaluate the Effects of P-glycoprotein Inhibition and Gastric Acid Suppression on Single-dose Pharmacokinetics of Vimseltinib in Healthy Adult Participants | $1.6M | 0 | 39 |
| A Phase 1, Open-label Study of the Pharmacokinetics, Safety, and Tolerability of Single-dose Vimseltinib in Participants with Hepatic Impairment Compared to Healthy Control Participants | $1.4M | 0 | 38 |
| AN OPEN-LABEL, MULTICENTER, PHASE 1B/2 STUDY OF REBASTINIB (DCC-2036) IN COMBINATION WITH PACLITAXEL TO ASSESS SAFETY, TOLERABILITY, AND PHARMACOKINETICS IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS | $1.3M | 0 | 1,563 |
| STUDY OF DCC-3014 IN PATIENTS WITH ADVANCED TUMORS AND TENOSYNOVIAL GIANT CELL TUMOR (MOTION) | $1.2M | 0 | 142 |
| A PHASE 1, RANDOMIZED, 2-PART OPEN-LABEL, SINGLE DOSE, CROSSOVER STUDY TO EVALUATE THE RELATIVE BIOAVAILABILITY AND SAFETY OF 2 FORMULATIONS OF REBASTINIB AND THE EFFECT OF A HIGH-FAT MEAL ON REBASTINIB PHARMACOKINETICS IN HEALTHY ADULT PARTICIPANTS | $1.0M | 0 | 18 |
| A SAFETY, TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES | $926,709 | 0 | 1,125 |
| A Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib (INSIGHT) | $819,276 | 0 | 110 |
| A MASTER PROTOCOL FOR THE MULTI-COHORT, OPEN-LABEL, PHASE 1/2 STUDY OF DCC-3084 AS MONOTHERAPY AND IN COMBINATION WITH OTHER ANTICANCER AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS DRIVEN BY THE MAPK PATHWAY | $781,942 | 0 | 100 |
| A Phase 1, Randomized, Open-Label, Crossover Study to Evaluate the Relative Bioavailability and Safety of 2 Formulations of DCC-3116 and the Food Effect on DCC-3116 Pharmacokinetics in Healthy Adult Participants | $760,766 | 0 | 5 |
| A PHASE 1, RANDOMIZED, OPEN-LABEL, CROSSOVER STUDY TO EVALUATE THE RELATIVE BIOAVAILABILITY AND SAFETY OF 2 FORMULATIONS OF DCC-3116 AND THE FOOD EFFECT ON DCC-3116 PHARMACOKINETICS IN HEALTHY ADULT PARTICIPANTS | $691,474 | 0 | 9 |
| STUDY OF VIMSELTINIB FOR TENOSYNOVIAL GIANT CELL TUMOR (MOTION) | $374,406 | 0 | 57 |
| A PHASE 1B/ STUDY OF REBASTINIB (DCC-2036) IN COMBINATION WITH PACLITAXEL IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS | $323,386 | 0 | 545 |
| A Multicenter Phase 1/2, Open-Label Study of DCC-3014 to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics in Patients with Advanced Tumors and Tenosynovial Giant Cell Tumor | $279,736 | 0 | 239 |
| A SAFETY, TOLERABILITY AND PK STUDY OF DCC-3116 IN PATIENTS WITH RAS OR RAF MUTANT ADVANCED OR METASTATIC SOLID TUMORS | $233,595 | 0 | 78 |
| STUDY OF DCC-3014 IN COMBINATION WITH AVELUMAB IN PATIENTS WITH ADVANCED OR METASTATIC SARCOMAS | $160,000 | 0 | 2 |
| A STUDY OF REBASTINIB (DCC-2036) IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS | $119,080 | 0 | 108 |
| PHASE 3 STUDY OF DCC-2618 VS PLACEBO IN ADVANCED GIST PATIENTS WHO HAVE BEEN TREATED WITH PRIOR ANTICANCER THERAPIES (INVICTUS) | $114,485 | 0 | 211 |
Payments by Medical Specialty
| Specialty | Total Paid | Doctors | Avg/Doctor |
|---|---|---|---|
| Hematology | $791,934 | 137 | $5,781 |
| Hematology & Oncology | $498,371 | 1,209 | $412.22 |
| Medical Oncology | $337,336 | 321 | $1,051 |
| Internal Medicine | $222,715 | 355 | $627.37 |
| Nurse Practitioner | $87,700 | 411 | $213.38 |
| Orthopaedic Surgery | $47,511 | 21 | $2,262 |
| Family | $45,928 | 521 | $88.15 |
| Surgery | $25,841 | 25 | $1,034 |
| Student in an Organized Health Care Education/Training Program | $24,287 | 99 | $245.32 |
| Specialist | $23,846 | 86 | $277.28 |
| Physician Assistant | $13,129 | 272 | $48.27 |
| Anatomic Pathology | $10,600 | 3 | $3,533 |
| Dermatology | $9,422 | 5 | $1,884 |
| Hospitalist | $7,146 | 18 | $396.98 |
| Adult Health | $6,954 | 140 | $49.67 |
| Surgical Oncology | $5,981 | 4 | $1,495 |
| Medical | $5,508 | 115 | $47.89 |
| Dermatopathology | $4,924 | 2 | $2,462 |
| Interventional Cardiology | $4,534 | 1 | $4,534 |
| General Acute Care Hospital | $4,258 | 2 | $2,129 |
| Hospice and Palliative Medicine | $4,179 | 8 | $522.37 |
| Gynecologic Oncology | $4,141 | 14 | $295.77 |
| Registered Nurse | $3,721 | 71 | $52.41 |
| Orthopaedic Trauma | $3,619 | 1 | $3,619 |
| Dentist | $3,500 | 1 | $3,500 |
| Acute Care | $3,318 | 79 | $42.00 |
| Pediatric Hematology-Oncology | $3,003 | 4 | $750.84 |
| Gastroenterology | $2,783 | 4 | $695.69 |
| Radiation Oncology | $1,915 | 64 | $29.92 |
| Gerontology | $1,790 | 38 | $47.10 |
| Obstetrics & Gynecology | $1,096 | 7 | $156.61 |
| Oncology | $954.60 | 18 | $53.03 |
| Primary Care | $592.12 | 15 | $39.47 |
| Family Medicine | $472.07 | 14 | $33.72 |
| Surgical | $470.69 | 9 | $52.30 |
| Pediatrics | $304.67 | 9 | $33.85 |
| Women's Health | $287.93 | 10 | $28.79 |
| General Practice | $204.59 | 8 | $25.57 |
| Critical Care Medicine | $196.84 | 7 | $28.12 |
| Ambulatory Care | $184.08 | 1 | $184.08 |
| Registered Nurse First Assistant | $183.06 | 2 | $91.53 |
| Neuroscience | $165.29 | 1 | $165.29 |
| Clinical Nurse Specialist | $163.20 | 4 | $40.80 |
| Diagnostic Radiology | $153.21 | 6 | $25.54 |
| Thoracic Surgery (Cardiothoracic Vascular Surgery) | $144.16 | 2 | $72.08 |
| Urology | $136.97 | 4 | $34.24 |
| Rheumatology | $132.43 | 3 | $44.14 |
| Anesthesiology | $110.64 | 2 | $55.32 |
| Anatomic Pathology & Clinical Pathology | $109.57 | 4 | $27.39 |
| Geriatric Medicine | $107.92 | 4 | $26.98 |
| Allergy & Immunology | $104.50 | 1 | $104.50 |
| Emergency | $91.09 | 3 | $30.36 |
| Family Health | $84.36 | 2 | $42.18 |
| Interventional Pain Medicine | $65.39 | 1 | $65.39 |
| Obstetrics | $60.00 | 1 | $60.00 |
| Clinical Cardiac Electrophysiology | $58.44 | 1 | $58.44 |
| Colon & Rectal Surgery | $57.48 | 2 | $28.74 |
| Nephrology | $44.80 | 2 | $22.40 |
| Dietitian, Registered | $44.21 | 1 | $44.21 |
| Oncology, Pediatrics | $43.01 | 1 | $43.01 |
| Legal Medicine | $42.97 | 1 | $42.97 |
| Therapeutic Radiology | $41.09 | 2 | $20.55 |
| Physical Medicine & Rehabilitation | $40.88 | 1 | $40.88 |
| Community Health | $35.66 | 2 | $17.83 |
| Cytopathology | $32.81 | 1 | $32.81 |
| Vascular Surgery | $32.81 | 1 | $32.81 |
| Optician | $31.49 | 1 | $31.49 |
| Otolaryngology | $31.25 | 2 | $15.63 |
| Independent Medical Examiner | $29.89 | 1 | $29.89 |
| Plastic Surgery | $23.90 | 1 | $23.90 |
| Obstetric, Inpatient | $23.54 | 1 | $23.54 |
| Infusion Therapy | $23.18 | 1 | $23.18 |
| Infectious Disease | $20.88 | 1 | $20.88 |
| Neurology | $20.04 | 1 | $20.04 |
| Pulmonary Disease | $20.00 | 1 | $20.00 |
| Neuromuscular Medicine | $18.78 | 1 | $18.78 |
| Podiatrist | $18.64 | 1 | $18.64 |
| Orthopaedic Surgery of the Spine | $18.04 | 1 | $18.04 |
| Athletic Trainer | $17.96 | 1 | $17.96 |
| Home Health | $17.54 | 1 | $17.54 |
| Ophthalmology | $16.19 | 1 | $16.19 |
| Obesity Medicine | $16.17 | 1 | $16.17 |
| Licensed Practical Nurse | $15.81 | 1 | $15.81 |
| Emergency Medicine | $14.15 | 1 | $14.15 |
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| Dr. Edward Benz, Md, MD | Hematology | Boston, MA | $746,999 | $0 |
| Mark Agulnik, Md, MD | Medical Oncology | Los Angeles, CA | $58,243 | $0 |
| Dr. Adam Burgoyne, M.d., Ph.d, M.D., PH.D | Hematology & Oncology | San Diego, CA | $50,111 | $0 |
| Dr. Seth Pollack, Md, MD | Hematology & Oncology | Chicago, IL | $43,721 | $0 |
| William Tap, Md, MD | Hematology & Oncology | New York, NY | $33,306 | $0 |
| Arlene Ortega, Np, NP | Nurse Practitioner | San Diego, CA | $33,305 | $0 |
| Mr. John Charlson, M.d, M.D | Hematology & Oncology | Milwaukee, WI | $31,990 | $0 |
| Dr. Dale Shepard, M.d., Ph.d, M.D., PH.D | Hematology & Oncology | Cleveland, OH | $30,427 | $0 |
| Dr. Arun Singh, M.d, M.D | Hematology & Oncology | Santa Monica, CA | $30,033 | $0 |
| Fadi Braiteh, M.d, M.D | Internal Medicine | Las Vegas, NV | $27,904 | $0 |
| Dr. Jason Sicklick, M.d, M.D | Surgery | La Jolla, CA | $25,193 | $0 |
| Shreyaskumar Patel | Medical Oncology | Houston, TX | $24,026 | $0 |
| Rebecca Ganzon, Aprn.cnp, APRN.CNP | Nurse Practitioner | Pickerington, OH | $22,054 | $0 |
| Dr. Ciara Kelly, Mb Bch Bao, MB BCH BAO | Medical Oncology | New York, NY | $21,592 | $0 |
| Mihaela Druta, M.d, M.D | Medical Oncology | Tampa, FL | $21,107 | $0 |
| Dr. Neeta Somaiah, M.d, M.D | Internal Medicine | Houston, TX | $20,432 | $0 |
| Gina D'amato, Md, MD | Internal Medicine | Atlanta, GA | $19,888 | $0 |
| Rashmi Chugh, Md, MD | Hematology | Ann Arbor, MI | $19,667 | $0 |
| Vinod Ravi, Md, MD | Medical Oncology | Houston, TX | $18,551 | $0 |
| Andrew Wagner, M.d, M.D | Hematology & Oncology | Boston, MA | $18,030 | $0 |
| Richard Riedel, Md, MD | Internal Medicine | Durham, NC | $17,369 | $0 |
| Vicki Keedy, Md, MD | Hematology & Oncology | Nashville, TN | $15,789 | $0 |
| Dr. Suzanne George, Md, MD | Medical Oncology | Boston, MA | $15,145 | $0 |
| Dr. Breelyn Wilky, Md, MD | Internal Medicine | Aurora, CO | $14,772 | $0 |
| Margaret Von-Mehren, M.d, M.D | Specialist | Philadelphia, PA | $14,513 | $0 |
Ad
Top Products
- QINLOCK $72.3M
- SUTENT $1.3M
Associated Products (3)
- QINLOCK $72.3M
- VIMSELTINIB $173,161
- ROMVIMZA $30,500
Payment Categories
- Food & Beverage $218,847
- Consulting $335,154
- Travel & Lodging $112,285
- Research $106.5M
About Deciphera Pharmaceuticals Inc.
Deciphera Pharmaceuticals Inc. has made $108.8M in payments to 4,229 healthcare providers, recorded across 31,262 transactions in the CMS Open Payments database. In 2024, the company paid $21.9M. The top product by payment volume is QINLOCK ($72.3M).
Payments were distributed across 84 medical specialties. The top specialty by payment amount is Hematology ($791,934 to 137 doctors).
Payment categories include: Food & Beverage ($218,847), Consulting ($335,154), Research ($106.5M), Travel & Lodging ($112,285).
Deciphera Pharmaceuticals Inc. is associated with 3 products in the CMS Open Payments database.